A Phase 2 Study of ABSK043 Combined With Osimertinib

Clinical trial NCT07710612 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07710612
Sponsor: Abbisko Therapeutics Co, Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

Start date: 2026-08-31
Primary completion: 2029-12-31
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.